clinical trials for glp-1 obesity meds actively recruiting From Post to Prescription: How is Social Media shaping the conversation on and on Pharmacotherapy Obesity? Amycretin — a novel obesity

Several studies suggest GLP-1 drugs may lower cancer risk

PALO ALTO, Calif., September 28, 2023 (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity

Millions of Medicare beneficiaries could save tens of thousands a year as the Feds make a multibillion dollar bet.

Brand names are referenced for educational context only and do not indicate that a specific branded product will be prescribed